Kaleido Biosciences is a clinical-stage healthcare company engaged in the discovery and development of novel chemistries to drive functions of the microbiome organ to treat disease and improve human health. The Company is advancing a robust pipeline of Microbiome Metabolic Therapies (MMTs) across a range of therapeutic areas, including rare genetic disorders.